In the time it takes to read this article, several people in the United States will likely experience a heart attack — according to the CDC, someone in the US suffers from one every 40 seconds.

That morbid statistic highlights the importance of coronary artery disease detection methods, and companies developing them.

One such company is Israeli startup AccuLine, which recently secured $4.2 million in seed funding for the development and commercialization of its CORA (Coronary Artery Risk Assessment) system, designed to improve the early detection of coronary artery disease (CAD), a leading cause of heart attacks.

CORA detects two bio-signals in the heart’s electrical activity, providing insights into coronary artery health. The system uses artificial intelligence and machine-learning algorithms to analyze this data, identifying patterns that may indicate CAD.

The CORA assessment improves upon current CAD diagnostic tools by means of a noninvasive, radiation-free test that evaluates three vital signs — the heart’s electrical activity, oxygen saturation levels and respiratory phase — in four minutes.

The system is designed to be operated by medical staff in various healthcare settings, with immediate results. By potentially replacing some existing stress test examinations, CORA could reduce medical expenses while maintaining diagnostic accuracy.

Keep reading at israel21c.org.

AccuLine Co-founder and CTO Benny Shani is a Technion alumnus.